Ngā Ārai Menin: He Rongoā Hou mō te Mate Pūkahukahu Myeloid Akut
Ko te mate pukupuku toto myeloid acute (AML) he mate pukupuku toto uaua, he rerekē hoki e tohuhia ana e te tipu clonal o ngā pūtau tupuna myeloid. Ahakoa te ahunga whakamua o te maimoatanga, he uaua tonu te whakaora i te AML, inā koa mō ngā tūroro he rerekētanga ira motuhake. Ngā rangahau hou kua whakaatuhia i roto i te puka. Toto te whakanui i te uara haumanu o ngā aukati Menin, me te whakaatu i tō rātou kaha ki te huri i te maimoatanga AML.
Te Tūranga o te Epigenetics i roto i te AML
Ko ngā whakarerekētanga epigenetic, pērā i te methylation DNA me te whakarerekētanga histone, he huringa whakahurihuri e whakahaere ana i te whakaaturanga ira me te kore e whakarerekē i te raupapa DNA. He mea nui ēnei huringa ki te whanaketanga o te AML. Mā te arotahi ki ēnei tikanga epigenetic whakahurihuri ka tukuna he huarahi rongoā auaha.
Ko ngā histones, arā, ngā pūmua nui i roto i te takai DNA, ka pāngia e ngā whakarerekētanga i muri i te whakamāoritanga pērā i te acetylation me te methylation, e pā ana ki te tuhi ira. Ko te Menin, he pūmua tautoko i whakakōrerohia e te ira MEN1, he mea nui mō te whakahaere i te epigenetic. Ka taunekeneke ki te histone methyltransferase KMT2A me ētahi atu hoa mahi hei whakahaere i te whakaaturanga ira. I roto i te AML, ka āwhina a Menin i ngā kaupapa tuhi oncogenic, inā koa mā te whakanui ake i ngā ira HOXA me MEIS1, koia ngā kaiārahi matua i roto i te AML kua whakarerekētia e KMT2A me te NPM1.
Ngā Ārai Menin: He Huarahi Hou i roto i te Maimoatanga AML
He ngota iti tino whiriwhiri ngā aukati Menin i hangaia hei whakakore i te taunekeneke i waenga i a Menin me KMT2A, ā, mā reira ka aukati i ngā ara whakawhiti oncogenic. Kua whakaatuhia e ēnei aukati he whai huatanga whakamiharo i roto i ngā rangahau haumanu me ngā rangahau haumanu, inā koa mō te AML kua whakarerekētia e KMT2A me te NPM1 kua whakarerekētia, e whai wāhi ana ki tētahi wāhanga nui o ngā take AML.
Kua whakaaetia te aukati Menin tuatahi, te revumenib (SNDX-5613), mō te whakamahinga haumanu, me ētahi atu, tae atu ki te ziftomenib (KO-539) me te bleximenib, e whai whakamātautau haumanu ana. I whakaatuhia e te whakamātautau AUGMENT-101 i eke te revumenib ki te reiti urupare whānui (ORR) o te 53% i roto i te AML kua hoki mai, kua uaua rānei te rongoā (R/R), me ngā pānga taha ka taea te whakahaere pērā i te whakaroa QTc me te mate rerekētanga. Waihoki, ko ngā hua wawe mai i ngā whakamātautau KOMET-001 me KOMET-008 e aromatawai ana i te ziftomenib i whakaatu i ngā reiti murunga me ngā kōtaha haumaru.
Kei te tūhuratia hoki ngā maimoatanga whakakotahi hei whakarei ake i te whai huatanga o ngā aukati Menin. Kua whakaatuhia e ngā rangahau e whakakotahi ana i te revumenib me ngā kaihoko hypomethylating pēnei i te azacitidine me te venetoclax e tata ana ki te 100% ngā reiti urupare i roto i ngā tūroro AML hauora me te kore hauora, ahakoa me whai rangahau anō me ngā rōpū nui ake.
Haumaru me ngā Aronga ā-Mārama
Ko ngā aukati Menin he pai te āhua o te haumaru, ā, ko te nuinga o ngā pānga taha ka taea te whakahaere me te whakakore. Ko ngā pānga kino noa ko ngā tohu o te puku, te cytopenias, me te mate rerekētanga. Ko ngā tohu whakaora hou i tukuna e te US FDA ki te revumenib me te ziftomenib e whakaatu ana i te hiranga o ngā aukati Menin ki te aro atu ki ngā hiahia kāore anō kia tutuki i roto i te maimoatanga AML.
Ko ngā raraunga haumanu whai hua mō ngā aukati Menin e tohu ana i tētahi taahiraa whakarerekētanga i roto i te rongoā AML, e tuku ana i te tumanako ki ngā tūroro he uaua ngā momo ira o mua. I te haere tonu o ngā rangahau, kua rite ēnei rongoā ki te tautuhi anō i te paerewa tiaki mō te AML.
Kei te whakapau kaha tonu a BIOOCUS International Medical Center ki te whakamahi i ngā hangarau hou pēnei i ngā aukati Menin hei whakarato i ngā maimoatanga auaha, whai hua hoki mō ngā tūroro o te ao katoa.